Zolmitriptan inhalation - Acorda Therapeutics
Alternative Names: CVT 427; Zolmitriptan inhalation powderLatest Information Update: 09 Apr 2024
At a glance
- Originator Civitas Therapeutics
- Developer Acorda Therapeutics
- Class Analgesics; Antimigraines; Indoles; Oxazolidinones; Small molecules; Tryptamines
- Mechanism of Action Serotonin 1B receptor agonists; Serotonin 1D receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Migraine
Most Recent Events
- 01 Apr 2024 Discontinued - Phase-I for Migraine (In volunteers) in USA (Inhalation) as company files for bankruptcy
- 28 Jan 2019 No recent reports of development identified for phase-I development in Migraine(In volunteers) in USA (Inhalation, Powder)
- 27 Apr 2017 Acorda Therapeutics terminates before initiation a phase II trial for Migraine